Tocophersolan.

Tocophersolan is the PEGylated succinate ester of alpha-tocopherol and releases that vitamin on hydrolysis. Both entries in one formula describe the same nutrient.

Esterase cleavage frees the natural-configuration alpha-tocopherol that does the chain-breaking work in membranes. The PEG succinate half is carrier, not nutrient.

Tocophersolan micelles carry curcumin through the aqueous layer and its P-glycoprotein inhibition reduces pumping back into the lumen. This is a standard curcumin delivery approach.

Resveratrol is limited less by permeability than by heavy conjugation and efflux at the intestinal wall. A tocophersolan micelle raises solubilised fraction and slows efflux.

CoQ10 uptake stalls at micelle formation because of its long isoprenoid tail. Tocophersolan supplies surfactant capacity that does not depend on bile output.

Cholecalciferol needs mixed micelles to reach the brush border. Tocophersolan is used where bile-dependent absorption is unreliable.

Retinol and its esters partition into micelles before uptake, and tocophersolan forms those micelles at low concentration.

MK-7 is highly lipophilic and its absorbed fraction tracks the fat and surfactant it is taken with. Tocophersolan raises the solubilised portion.

Ascorbate regenerates the tocopheroxyl radical produced when released alpha-tocopherol quenches lipid peroxidation. The two antioxidants work at opposite sides of the membrane interface.

Sirolimus is a P-glycoprotein substrate cleared by CYP3A4, and tocophersolan inhibits that efflux pump. Co-formulation raises how much of the compound survives the intestinal wall.

Astaxanthin is a highly lipophilic xanthophyll with poor aqueous dispersion, and tocophersolan forms mixed micelles above its critical micelle concentration that carry such molecules into the absorptive phase. The pairing is a delivery decision, not a nutrient interaction. Micellar solubilisation of carotenoids by amphiphilic surfactants is established formulation chemistry.

Lutein needs a lipid or surfactant phase to reach the mixed micelle stage of digestion, which is why it is usually presented in oil or in a beadlet. Tocophersolan provides that phase in a water-dispersible format. The dependence on micellar solubilisation is a settled feature of carotenoid absorption.

Zeaxanthin behaves like lutein in the gut lumen and reaches the enterocyte only from the mixed micelle. A surfactant that self-assembles into micelles at low concentration lets a dry powder format do what an oil suspension usually does. The mechanism is physical solubilisation rather than any change to zeaxanthin itself.

Lycopene is the least polar of the common dietary carotenoids and the most dependent on a lipid vehicle for absorption. Tocophersolan raises its dispersion in aqueous media and keeps it in the micellar phase. The crystalline form of lycopene in the raw material still limits how much any surfactant can help.

Beta-carotene absorption tracks the amount of lipid and surfactant present at the same meal. A tocophersolan-based dispersion supplies the surfactant part without adding a large fat load. Uptake still varies widely between individuals for reasons that formulation does not control.

Tocotrienols share the chromanol head of tocopherols but carry an unsaturated tail and are poorly absorbed from a dry format without a lipid or surfactant. Tocophersolan is itself a tocopherol derivative, so it disperses them readily. Whether the added absorption changes any tissue endpoint has not been shown.

Quercetin aglycone dissolves poorly in water and is also a substrate for intestinal efflux transport. Tocophersolan raises its apparent solubility through micellisation and inhibits P-glycoprotein-mediated efflux at the brush border. Both effects are documented for this surfactant class in absorption models.

Berberine has notoriously low oral bioavailability, driven in large part by P-glycoprotein efflux back into the gut lumen. Tocophersolan inhibits that transporter, which is the standard reason it is chosen as an excipient for efflux substrates. This is an absorption effect and says nothing about what berberine then does.

Medium-chain triglycerides give a lipid core that tocophersolan can emulsify, producing a self-emulsifying system finer than either component makes alone. The combination is standard practice for lipophilic actives in softgels. The pairing is formulation convention rather than a nutritional synergy.

Phospholipids and tocophersolan are frequently co-used because the phospholipid builds the bilayer or the interface and the surfactant stabilises the droplet size. Each contributes a different part of the emulsion structure. This is a manufacturing choice with no claim attached.

Phosphatidylcholine forms the lamellar phase in phytosome-style and liposomal preparations, and tocophersolan is added as a co-surfactant to reduce particle size and resist aggregation. The two act on different parts of the same physical problem. Read this as formulation practice, not a combined nutrient effect.

Phylloquinone is a fat-soluble vitamin whose absorption from a dry or aqueous format is limited without a lipid or surfactant phase. Tocophersolan provides that phase. The specific quantitative gain depends on the finished format and is not a fixed number.

Tocophersolan is d-alpha-tocopherol esterified to succinic acid and then to polyethylene glycol, so intestinal and cellular esterases hydrolysing it release free d-alpha-tocopherol. A formula carrying both is therefore counting the same vitamin twice unless the label states which figure includes the ester. This is straightforward ester chemistry.

Riboflavin appears alongside tocophersolan in the co-study record, generally as a marker compound or a payload in dispersion work rather than as a nutritional pairing. Nothing in that record supports a combined effect in people. Read it as a formulation context.